A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis - Milan 2023

Basic mechanism and novel treatment targets in pulmonary fibrosis

Chair(s): ARGYRIS TZOUVELEKIS, Vanesa Vicens Zygmunt

Session type: Poster session

A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis

Seidai Sato

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

A multicenter study of extracellular vesicles profile in bronchoalveolar lavage from patients affected by IPF, HP and sarcoidosis

Miriana D'alessandro

Poster

Abstract

Iron status and the risk of idiopathic pulmonary fibrosis: a mendelian randomization study

Jian Zhou

Abstract

Microcomputed tomography to study the in vivo development of IPF-like disease in conditional Nedd4-2 deficient mice

Dominik Leitz

Poster

Abstract

CycloZ reduces inflammation in bleomycin-induced idiopathic pulmonary fibrosis model mice.

Seoyeong Baek

Poster

Abstract

Regenerative capacity of alveolar type 2 cells is proportionally reduced following disease progression in IPF-derived organoid cultures

Hyeon Kyu Choi

Abstract

Hyaluronic acid decorated-liposome loaded with Imatinib (XHALIP): delivered intratracheally are effective in a Bleomycin model of lung fibrosis

Federica Meloni

Poster

Abstract

Imatinib treatment for fibrotic lung disorders: ex vivo assessment on human lungs.

Sara Bozzini

Poster

Abstract

Fcor/FOXO1 axis regulates GLUT1-mediated mitochondrial oxidative stress and metabolic reprogramming in angiotensin II-induced fibroblast activation

Wei Wang

Abstract

Intratracheal administration of a PROTAC with subnanomolar potency induces BRD4 degradation in the lung without systemic target engagement

Ulf Hedstrom

Poster

Abstract

Novel waveform analysis reveals persistent pathophysiological changes in rodent model of pulmonary fibrosis

Maria Volovaya

Poster

Abstract

Data-driven processing of electronic medical record (EMR) and serum exosome proteomics data of idiopathic pulmonary fibrosis (IPF) patients identified pathological networks and its regulatory molecules

Mari Nogami-itoh

Poster

Abstract

CycloZ improves pulmonary fibrosis in bleomycin-induced idiopathic pulmonary fibrosis model mice by modulating the pathogenic transcriptome.

Dohyun Lee

Poster

Abstract

A clinical-stage RNAi therapeutic candidate for IPF mediates durable MMP7 silencing in nonhuman primates and human lung tissue

Tingting Yuan

Poster

Abstract

Abnormal phosphorylation of Per2 induces myofibroblast transformation and promotes the development of pulmonary fibrosis

Mei Chen

Abstract

Use of invasive lung function assessment (DSI/Buxco) to quanity changes in lung function parameters in a rat bleomycin model of lung fibrosis.

Mary Mcelroy

Abstract

Impact of Bifidobacterium longum BB536 on nausea caused by pirfenidone in a mouse model of pellagra

Koji Kuronuma

Poster

Abstract

Bleomycin does not directly cause fibrosis in precision-cut lung slices, PCLS

Satoshi Kanazawa

Poster

Abstract

Preclinical evaluation of Ezetimibe for repurposing to pulmonary fibrosis.

Chanho Lee

Poster

Abstract

A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis

Seidai Sato

Poster

Abstract

Aging disturbed lysosomes to modulate efferocytosis-induced SPP1-expressing macrophage and inhibit pulmonary fibrosis reversal

Yue Zhang

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}